1. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project. Genet. Med. 13 (2011) 230-254
  2. Mutational analysis for biotinidase deficiency of a Greek patients’ cohort ascertained through expanded newborn screening. J. Hum. Genet. 56 (2011) 861-865
  3. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet.Med. (2012)
  4. Expanded Newborn Screening in Greece: Thirty months of experience. J. Inherit. Metab. Dis. DOI: 10.1007/s10545-011-9302-z.
  5. Mutational analysis for biotinidase deficiency of a Greek patients’ cohort ascertained through expanded newborn screening. J. Hum. Genetics 56, 861-865 (2011)
  6. Characterization of the molecular spectrum of Medium-Chain Acyl-CoA Dehydrogenase Deficiency in a Greek newborns cohort: Identification of a novel variant. Clin Biochem 45, 1167-72 (2012)
  7. High incidence of partial biotinidase deficiency cases in newborns of Greek origin. Gene 524 (2013) 361–362
  8. Targeted Next-Generation Sequencing in Routine Clinical Practice: Detection of Inherited Mutations in CFTR & BRCA Genes on MiSeq Platform». Under review, 2013, Plos One
  9. High incidence of the C563T mutation among Greek newborns with Mediterranean Erythrocyte Glucose – 6 – Phosphate Dehydrogenase Deficiency. Under review (2015) Journal of Peadiatrics and Child Health
  10. Efficacy of next generation technology versus less extended panels for CFTR carrier screening in the heterogenous Greek population. European Journal of Human Genetics.2015, under review